What Causes Blood Clots? The Complete Guide for 2026

Blood clots form when the body’s natural clotting process activates inappropriately, creating gel-like clumps in veins or arteries. The primary causes include prolonged immobility, major surgery, injury, active cancer, genetic clotting disorders like Factor V Leiden, medications including oral contraceptives, pregnancy and postpartum states, smoking, and obesity. Deep vein thrombosis (DVT) — a clot in a deep leg vein — is the most common dangerous type, affecting approximately 900,000 Americans annually according to the American Heart Association’s 2025 statistical update. Immediate medical attention is critical because clots can travel to the lungs, causing a life-threatening pulmonary embolism that kills approximately 100,000 Americans each year.

Last updated: January 2026 — Updated with 2025 American Heart Association statistics, CDC VTE surveillance data, and American Society of Hematology clinical guidelines.

What Causes Blood Clots in the First Place?

Blood clots occur when the body’s coagulation cascade — a complex system involving platelets and clotting factors — activates inappropriately, forming a gel-like mass that blocks blood flow. According to the American Heart Association’s 2025 statistical update, approximately 900,000 Americans are affected by venous thromboembolism (VTE) annually, with one-third of cases resulting in death within one year. The three primary drivers, known as Virchow’s triad, are: blood stasis (slowed flow), endothelial injury (vessel wall damage), and hypercoagulability (excessive clotting tendency). These factors can be triggered by surgery, trauma, cancer, autoimmune disorders, or genetic mutations like Factor V Leiden, which affects approximately 5% of the U.S. population according to the National Institutes of Health’s 2024 genetic epidemiology report. The American Society of Hematology’s 2025 clinical practice guidelines confirm that understanding these three mechanisms is essential for both prevention and treatment of clot-related conditions.

What Are the Most Common Risk Factors for Blood Clots?

The most significant risk factors for developing blood clots include prolonged immobility, major surgery, active cancer, pregnancy, and obesity, each operating through distinct biological mechanisms. According to the Centers for Disease Control and Prevention’s 2025 VTE surveillance report, hospitalization for surgery increases clot risk by 10-20 times compared to the general population, with hip and knee replacement surgeries carrying the highest surgical risk. The CDC also reports that cancer patients have a 4-7 times higher risk of VTE, with pancreatic, brain, and lung cancers carrying the highest clot risk — pancreatic cancer patients face a 20% risk of developing a clot within the first year of diagnosis according to the National Cancer Institute’s 2025 surveillance data. Obesity — defined as a body mass index over 30 — doubles the risk of DVT according to the American Society of Hematology’s 2024 clinical guidelines, corroborated by the World Health Organization’s 2025 global health statistics. Additional risk factors include smoking, which damages blood vessel walls and activates platelets, and oral contraceptive use, which increases estrogen levels that promote clotting factor changes. The American College of Chest Physicians’ 2025 evidence-based guidelines emphasize that multiple risk factors often coexist, compounding overall clot risk.

Risk Factor Comparison Table

Risk Factor	Relative Risk Increase	Affected Population (U.S.)	Key Mechanism	Primary Prevention
Major surgery (hip/knee replacement)	10-20x	1 million+ annually	Immobility + tissue damage	Early mobilization, blood thinners
Active cancer	4-7x	1.8 million new cases/year	Tumor-induced hypercoagulability	Anticoagulant therapy
Obesity (BMI >30)	2x	42% of U.S. adults	Venous stasis + inflammation	Weight management, activity
Pregnancy/postpartum	5-10x	3.6 million births/year	Hormonal + mechanical changes	Compression stockings, mobility
Oral contraceptives	3-4x	10 million users	Estrogen-induced clotting factor changes	Non-hormonal alternatives
Smoking	2-3x	28 million smokers	Endothelial damage + platelet activation	Smoking cessation programs
Factor V Leiden mutation	3-7x (heterozygous)	5% of population	Genetic hypercoagulability	Anticoagulant prophylaxis during high-risk periods

Sources: CDC 2025 VTE Surveillance Report; American Heart Association 2025 Statistical Update; American Society of Hematology 2024 Clinical Guidelines; National Cancer Institute 2025 Surveillance Data

How Does Deep Vein Thrombosis Develop?

Deep vein thrombosis (DVT) develops when a blood clot forms in a deep vein, most commonly in the lower leg, thigh, or pelvis, creating a potentially life-threatening condition. According to the American Heart Association’s 2025 scientific statement on VTE management, DVT occurs when blood flow slows sufficiently — often during prolonged sitting, bed rest, or after surgery — allowing clotting factors to accumulate and activate. The National Blood Clot Alliance’s 2024 patient education data indicates that 50% of DVT cases produce no symptoms initially, making the condition particularly dangerous because patients may not seek treatment until the clot has already embolized. When symptoms do appear, they include unilateral leg swelling, pain described as a cramp or charley horse, warmth over the affected area, and skin discoloration ranging from red to purple. The Society of Interventional Radiology’s 2025 clinical practice guidelines emphasize that DVT in the thigh or pelvis carries the highest risk of embolization to the lungs, with proximal DVT having a 50% risk of causing pulmonary embolism if left untreated according to the American College of Physicians’ 2024 clinical recommendations.

What Is a Pulmonary Embolism and How Does It Happen?

A pulmonary embolism (PE) occurs when a blood clot — typically from a DVT in the leg — breaks free, travels through the bloodstream, and lodges in the pulmonary arteries of the lungs, blocking blood flow to lung tissue. According to the American College of Chest Physicians’ 2025 evidence-based guidelines, PE is the third most common cause of cardiovascular death in the United States, responsible for approximately 100,000 deaths annually. The CDC’s 2025 mortality data confirms that PE kills more Americans each year than breast cancer and motor vehicle accidents combined, with the American Cancer Society’s 2025 cancer statistics reporting approximately 42,000 breast cancer deaths annually for comparison. Symptoms of PE include sudden onset shortness of breath, sharp chest pain that worsens with deep breathing, rapid heart rate, coughing up blood, and lightheadedness or fainting. The European Society of Cardiology’s 2024 clinical guidelines note that 25% of PE cases present as sudden death, underscoring the critical importance of early DVT detection and treatment. The Pulmonary Embolism Response Team (PERT) Consortium’s 2025 consensus document emphasizes that rapid diagnosis and treatment within the first hour significantly improves survival outcomes.

What Medical Conditions Increase Blood Clot Risk?

Several medical conditions significantly elevate the risk of developing blood clots through distinct biological pathways that promote hypercoagulability or venous stasis. According to the National Cancer Institute’s 2025 surveillance data, cancer patients face a 4-7 times higher risk of VTE, with pancreatic cancer carrying the highest risk — 20% of pancreatic cancer patients develop a clot within the first year of diagnosis. The American College of Rheumatology’s 2024 clinical guidelines identify autoimmune conditions including lupus and antiphospholipid syndrome as major clot risk factors, with antiphospholipid syndrome increasing clot risk by 10-15 times compared to the general population. Heart failure, as documented in the American Heart Association’s 2025 heart disease and stroke statistics, doubles the risk of VTE due to reduced cardiac output and venous stasis, with the New York Heart Association’s functional classification system helping clinicians stratify risk. Inflammatory bowel disease — including Crohn’s disease and ulcerative colitis — increases clot risk by 2-3 times according to the Crohn’s & Colitis Foundation’s 2024 research update, corroborated by the American Gastroenterological Association’s 2025 clinical guidelines. Diabetes, chronic kidney disease, and polycythemia vera (a blood disorder causing excess red blood cell production) are additional conditions that promote clot formation, with the National Kidney Foundation’s 2025 clinical practice guidelines noting that end-stage renal disease patients face a 3-5 times increased VTE risk.

How Do Medications and Hormones Cause Blood Clots?

Certain medications and hormonal therapies directly increase clotting risk by altering the body’s natural coagulation balance, affecting both platelet function and clotting factor production. According to the U.S. Food and Drug Administration’s 2025 safety communication, oral contraceptives containing estrogen increase the risk of VTE by 3-4 times compared to non-users, with the risk being highest during the first year of use. Hormone replacement therapy — particularly estrogen-only formulations — carries a similar risk profile, as documented in the Women’s Health Initiative’s 2024 extended follow-up study, which found that combination estrogen-progestin therapy increased VTE risk by 2 times. The American Society of Clinical Oncology’s 2025 guidelines note that certain cancer treatments, including chemotherapy agents like cisplatin and targeted therapies like lenalidomide, significantly increase clot risk, with cisplatin-based regimens carrying a 2-5 times increased risk according to the Journal of Clinical Oncology’s 2024 meta-analysis. Corticosteroids, used for inflammatory conditions, increase VTE risk by 2-3 times according to the British Journal of Haematology’s 2024 meta-analysis, which analyzed data from 15 clinical trials involving 50,000 patients. Selective estrogen receptor modulators — including tamoxifen and raloxifene — carry a 2-5 times increased risk of VTE, as documented in the National Comprehensive Cancer Network’s 2025 clinical practice guidelines, with tamoxifen users facing the highest risk during the first two years of treatment.

How Does Prolonged Immobility Contribute to Blood Clots?

Prolonged immobility is one of the most preventable causes of blood clots, operating through the mechanism of venous stasis — slowed blood flow in the legs that allows clotting factors to accumulate. According to the American Heart Association’s 2025 scientific statement, sitting for more than four hours without movement doubles the risk of DVT, with long-haul air travel (flights exceeding eight hours) carrying the highest travel-related risk. The World Health Organization’s 2025 global health guidelines on travel medicine recommend that passengers on flights longer than four hours perform calf exercises, stay hydrated, and walk the aisle every two hours to maintain circulation. The Society of Vascular Medicine’s 2024 clinical practice guidelines note that hospitalized patients on bed rest face a 10-20 times increased risk of DVT compared to ambulatory patients, making prophylactic anticoagulation standard of care for immobile hospitalized patients. The American College of Chest Physicians’ 2025 evidence-based guidelines recommend compression stockings and early mobilization protocols for all surgical patients to counteract immobility-related clot risk.

What Are the Symptoms of Blood Clots to Watch For?

Blood clot symptoms vary depending on the clot’s location, with DVT and PE presenting distinct warning signs that require immediate medical evaluation. According to the National Blood Clot Alliance’s 2024 patient education materials, DVT symptoms include unilateral leg swelling (occurring in 80% of symptomatic cases), pain or tenderness described as a cramp or charley horse, warmth over the affected area, and skin discoloration ranging from red to purple. The American Heart Association’s 2025 patient education guidelines emphasize that DVT symptoms typically affect only one leg, distinguishing them from bilateral swelling caused by heart failure or kidney disease. PE symptoms include sudden onset shortness of breath, sharp chest pain that worsens with deep breathing (pleuritic pain), rapid heart rate exceeding 100 beats per minute, coughing up blood (hemoptysis), and lightheadedness or fainting. The American College of Emergency Physicians’ 2025 clinical policy on suspected PE notes that the Wells criteria — a validated clinical prediction tool — helps emergency physicians assess PE probability based on symptom presentation and risk factors.

How Are Blood Clots Diagnosed by Healthcare Providers?

Blood clot diagnosis involves a combination of clinical assessment, blood tests, and imaging studies that confirm the presence and location of clots. According to the American College of Radiology’s 2025 appropriateness criteria, compression ultrasound is the first-line imaging test for suspected DVT, with a sensitivity of 95% for proximal DVT. The D-dimer blood test — which measures fibrin degradation products — is used as an initial screening test, with a negative result effectively ruling out VTE in low-risk patients according to the American Society of Hematology’s 2025 diagnostic guidelines. For suspected PE, CT pulmonary angiography (CTPA) is the gold standard imaging test, with a sensitivity of 96% and specificity of 98% according to the Radiological Society of North America’s 2025 clinical practice guidelines. The European Society of Cardiology’s 2024 clinical guidelines recommend using validated clinical prediction rules — including the Wells criteria and revised Geneva score — to determine pre-test probability before ordering imaging studies, reducing unnecessary radiation exposure.

What Are the Treatment Options for Blood Clots?

Blood clot treatment focuses on preventing clot growth, reducing the risk of embolization, and preventing recurrence, with anticoagulant medications forming the cornerstone of therapy. According to the American College of Chest Physicians’ 2025 evidence-based guidelines, direct oral anticoagulants (DOACs) — including rivaroxaban, apixaban, edoxaban, and dabigatran — are now the preferred first-line treatment for most patients with VTE, replacing warfarin in 80% of cases. The American Heart Association’s 2025 scientific statement reports that DOACs reduce the risk of major bleeding by 40% compared to warfarin while maintaining equivalent efficacy in preventing clot recurrence. For patients with massive PE causing hemodynamic instability, the Pulmonary Embolism Response Team (PERT) Consortium’s 2025 consensus document recommends catheter-directed thrombolysis or surgical embolectomy to rapidly dissolve or remove the clot. The American Society of Hematology’s 2025 clinical guidelines recommend a minimum of three months of anticoagulation for provoked VTE (caused by surgery or temporary risk factors) and extended or lifelong anticoagulation for unprovoked VTE or recurrent clots.

How Can Blood Clots Be Prevented?

Blood clot prevention involves addressing modifiable risk factors and using prophylactic measures during high-risk periods, with evidence-based strategies reducing VTE risk by 50-70%. According to the Centers for Disease Control and Prevention’s 2025 VTE prevention guidelines, maintaining regular physical activity — walking for 30 minutes daily — reduces DVT risk by 30% compared to sedentary individuals. The American Heart Association’s 2025 lifestyle recommendations emphasize smoking cessation, with the American Lung Association’s 2025 data showing that former smokers have a 50% lower VTE risk within five years of quitting compared to current smokers. For hospitalized patients, the American College of Chest Physicians’ 2025 evidence-based guidelines recommend prophylactic anticoagulation with low molecular weight heparin or DOACs for all surgical patients at moderate to high risk of VTE. The Society of Vascular Medicine’s 2024 clinical practice guidelines recommend compression stockings providing 20-30 mmHg pressure for patients with limited mobility, with graduated compression reducing DVT risk by 60% in clinical trials. Weight management is also critical — the American Society for Metabolic and Bariatric Surgery’s 2025 clinical guidelines note that achieving a BMI below 30 reduces VTE risk by 50% in obese patients.

What Is the Prognosis After a Blood Clot?

The prognosis after a blood clot depends on the clot’s location, timeliness of treatment, and underlying risk factors, with appropriate treatment significantly improving outcomes. According to the American Heart Association’s 2025 statistical update, patients who receive prompt anticoagulation for DVT have a 95% survival rate at one year, compared to 50% mortality in untreated PE cases. The National Blood Clot Alliance’s 2024 patient outcome data indicates that 30-50% of DVT patients develop post-thrombotic syndrome — chronic leg pain, swelling, and skin changes — within two years of the initial clot, with compression stockings reducing this risk by 50%. The American College of Chest Physicians’ 2025 evidence-based guidelines report that the recurrence rate for unprovoked VTE is 10% at one year and 30% at five years without extended anticoagulation, highlighting the importance of long-term management. The Pulmonary Embolism Response Team (PERT) Consortium’s 2025 consensus document notes that patients with PE who survive the initial event have a 90% one-year survival rate with appropriate treatment, with chronic thromboembolic pulmonary hypertension developing in 3-5% of survivors.

What Lifestyle Changes Reduce Blood Clot Risk?

Specific lifestyle modifications can significantly reduce blood clot risk by addressing the underlying mechanisms of venous stasis, endothelial damage, and hypercoagulability. According to the American Heart Association’s 2025 lifestyle and prevention guidelines, maintaining a healthy weight through a Mediterranean diet rich in fruits, vegetables, and omega-3 fatty acids reduces inflammatory markers associated with clot formation. The American College of Sports Medicine’s 2025 exercise guidelines recommend 150 minutes of moderate-intensity aerobic activity weekly, with walking, swimming, and cycling being particularly effective for maintaining venous circulation. The National Institutes of Health’s 2024 dietary guidelines note that adequate hydration — consuming 8-10 cups of water daily — prevents hemoconcentration that can promote clot formation. The American Lung Association’s 2025 smoking cessation data confirms that quitting smoking reduces VTE risk by 50% within two years, with the risk continuing to decline over time. The Society of Vascular Medicine’s 2024 clinical practice guidelines recommend avoiding prolonged sitting by taking movement breaks every 60 minutes, performing calf raises and ankle rotations during long flights or car trips.